院前与转运医学中外周血管活性药物给药的安全性(SPOTLESS-2):一项前瞻性观察性队列研究
该前瞻性观察性队列研究纳入2022年4月至2023年8月由Lifeflight Medicine转运的468例经外周静脉套管接受肾上腺素或去甲肾上腺素的患者,主要终点为外周给药的安全性。去甲肾上腺素是最常见输注药物(72%),中位剂量0.1 μg/kg/min,肾上腺素中位剂量0.13 μg/kg/min;最常见输注部位为前肘窝(78%),最常见适应证为脓毒性休克(47%),中位输注时长85分钟。93.4%的患者未发生事件;31例发生事件者中,13例(2.8%)为给药相关轻微技术问题,14例(3%)为影响患者护理的轻微并发症,4例(0.8%)需转运途中转为中央通路;24小时随访无组织并发症。作者认为,肾上腺素和去甲肾上腺素在院前与转运医学环境中经外周给药可能安全,总体并发症风险低。
要点
- 468例院前与转运患者经外周静脉输注肾上腺素或去甲肾上腺素,93.4%未发生事件。
- 去甲肾上腺素为最常见输注药物(72%),中位剂量0.1 μg/kg/min;肾上腺素中位剂量0.13 μg/kg/min。
- 前肘窝为最常见输注部位(78%),脓毒性休克为最常见适应证(47%),中位输注时长85分钟。
- 31例发生事件:13例(2.8%)给药轻微技术问题,14例(3%)影响护理的轻微并发症,4例(0.8%)转运途中转为中央通路。
- 24小时随访无组织并发症;作者认为外周给药可能安全、总体并发症风险低。
适用人群与场景
- 2022年4月至2023年8月由Lifeflight Medicine转运、经外周静脉套管接受肾上腺素或去甲肾上腺素的患者,共468例纳入分析。
- 患者以男性为主(60%),中位年龄64岁,74%经旋翼机转运。
处置流程与药物剂量
- 经外周静脉套管输注去甲肾上腺素(最常见,72%),中位剂量0.1 μg/kg/min;肾上腺素中位剂量0.13 μg/kg/min。
- 最常见输注部位为前肘窝(78%),中位输注时长85分钟。
- 转运途中4例(0.8%)因外周通路问题转为中央通路。
研究设计与关键结果
- 前瞻性观察性队列研究,筛查656例,468例符合纳入标准,由Lifeflight Medicine于2022年4月至2023年8月转运。
- 主要终点为外周肾上腺素和去甲肾上腺素的安全性:93.4%的患者未发生事件。
- 31例发生事件:13例(2.8%)给药相关轻微技术问题,14例(3%)影响患者护理的轻微并发症,4例(0.8%)转运途中需转为中央通路。
- 24小时随访无组织并发症;脓毒性休克为最常见适应证(47%)。
证据类型、等级与局限
- 证据类型:前瞻性观察性队列研究。
- 试验注册:澳大利亚与新西兰临床试验注册中心(ACTRN12622000404729)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,肾上腺素和去甲肾上腺素在院前与转运医学环境中经外周给药可能安全,总体并发症风险低。
- 研究中4例(0.8%)在转运途中因外周通路问题转为中央通路。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: Adrenaline and noradrenaline are cornerstones of critical care. Traditionally, delivery of these drugs has been through central venous access due to concerns over the safety of peripheral venous access. However, central venous access also may lead to delays and complications, so there is increasing use of peripheral vasoactive drugs. There is evidence for the safety of peripheral administration in controlled theatre and intensive care settings but limited evidence in Prehospital and Retrieval Medicine.
METHODS: We conducted a prospective, observational cohort study including patients transferred by Lifeflight Medicine from April 2022 to August 2023. The primary outcome was to establish the safety of peripheral adrenaline and noradrenaline. Patients receiving adrenaline or noradrenaline via peripheral intravenous cannula were included and data on venous access, drug delivery, and complications during transfer was collected. Patients were followed to 24 h post arrival to the receiving facility.
RESULTS: A total of 656 patients were screened, 468 met the inclusion criteria. Patients were predominantly men (60%), median age of 64, 74% of patients were transferred by rotary wing. Noradrenaline was the most common infusion (72%) with a median dose of 0.1 μg/kg/min, and 0.13 μg/kg/min for adrenaline. The anterior cubital fossa was the most common infusion site (78%). Septic shock was the most common indication (47%). The median duration of infusion was 85 min. 93.4% of patients experienced no events with the peripheral infusion; of the remaining 31 patients, 13 (2.8%) had minor technical issues with drug delivery, 14 (3%) had minor complications affecting patient care and 4 (0.8%) required conversion to central access in transit. There were no tissue complications at 24 h follow-up.
CONCLUSION: Our data suggests that adrenaline and noradrenaline may be safely administered peripherally in Prehospital and Retrieval Medicine environments, with a low overall risk of complications.
TRIAL REGISTRATION: The study was pre-registered on the Australian and New Zealand Clinical Trials Registry (ACTRN12622000404729).
参考来源
- Greaves RL, Quay A, Bolot R, et al. Safety of Peripheral Vasoactive Drug Administration in Prehospital and Retrieval Medicine (SPOTLESS-2): A Prospective Observational Cohort Study. Acad Emerg Med. 2026. PMID: 41947342. doi:10.1111/acem.70271
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。